Vinay Choubey

Dr. Vinay Choubey

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PWPrzemyslaw Wareski
Przemyslaw Wareski
AVAnnika Vaarmann
Annika Vaarmann
VCVinay Choubey
Vinay Choubey
DSDzhamilja Safiulina
Dzhamilja Safiulina
JLJoanna Liiv
Joanna Liiv
AKAllen Kaasik
Allen Kaasik
Recent studies indicate that regulation of cellular oxidative capacity through enhancing mitochondrial biogenesis may be beneficial for neuronal recovery and survival in human neurodegenerative disorders. The peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) has been shown to be a master regulator of mitochondrial biogenesis and cellular energy metabolism in muscle and liver. The aim of our study was to establish whether PGC-1alpha and PGC-1beta control mitochondrial density also in neurons and if these coactivators could be up-regulated by deacetylation. The results demonstrate that PGC-1alpha and PGC-1beta control mitochondrial capacity in an additive and independent manner. This effect was observed in all studied subtypes of neurons, in cortical, midbrain, and cerebellar granule neurons. We also observed that endogenous neuronal PGC-1alpha but not PGC-1beta could be activated through its repressor domain by suppressing it. Results demonstrate also that overexpression of SIRT1 deacetylase or suppression of GCN5 acetyltransferase activates transcriptional activity of PGC-1alpha in neurons and increases mitochondrial density. These effects were mediated exclusively via PGC-1alpha, since overexpression of SIRT1 or suppression of GCN5 was ineffective where PGC-1alpha was suppressed by short hairpin RNA. Moreover, the results demonstrate that overexpression of PGC-1beta or PGC-1alpha or activation of the latter by SIRT1 protected neurons from mutant alpha-synuclein- or mutant huntingtin-induced mitochondrial loss. These evidences demonstrate that activation or overexpression of the PGC-1 family of coactivators could be used to compensate for neuronal mitochondrial loss and suggest that therapeutic agents activating PGC-1 would be valuable for treating neurodegenerative diseases in which mitochondrial dysfunction and oxidative damage play an important pathogenic role.

1 March 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
VCVinay Choubey
Vinay Choubey
DSDzhamilja Safiulina
Dzhamilja Safiulina
AVAnnika Vaarmann
Annika Vaarmann
MCMichal Cagalinec
Michal Cagalinec
PWPrzemyslaw Wareski
Przemyslaw Wareski
AKAllen Kaasik
Allen Kaasik
Parkinson disease is characterized by the accumulation of aggregated α-synuclein as the major component of the Lewy bodies. α-Synuclein accumulation in turn leads to compensatory effects that may include the up-regulation of autophagy. Another common feature of Parkinson disease (PD) is mitochondrial dysfunction. Here, we provide evidence that the overactivation of autophagy may be a link that connects the intracellular accumulation of α-synuclein with mitochondrial dysfunction. We found that the activation of macroautophagy in primary cortical neurons that overexpress mutant A53T α-synuclein leads to massive mitochondrial destruction and loss, which is associated with a bioenergetic deficit and neuronal degeneration. No mitochondrial removal or net loss was observed when we suppressed the targeting of mitochondria to autophagosomes by silencing Parkin, overexpressing wild-type Mitofusin 2 and dominant negative Dynamin-related protein 1 or blocking autophagy by silencing autophagy-related genes. The inhibition of targeting mitochondria to autophagosomes or autophagy was also partially protective against mutant A53T α-synuclein-induced neuronal cell death. These data suggest that overactivated mitochondrial removal could be one of the contributing factors that leads to the mitochondrial loss observed in PD models.

15 May 2013 in Journal of Cell Science
Verified
Journal Article
Open access
MCMichal Cagalinec
Michal Cagalinec
DSDzhamilja Safiulina
Dzhamilja Safiulina
MLMailis Liiv
Mailis Liiv
JLJoanna Liiv
Joanna Liiv
VCVinay Choubey
Vinay Choubey
AKAllen Kaasik
Allen Kaasik
Summary: Mitochondrial fusion–fission dynamics play a crucial role in many important cell processes. These dynamics control mitochondrial morphology, which in turn influences several important mitochondrial properties including mitochondrial bioenergetics and quality control, and they appear to be affected in several neurodegenerative diseases. However, an integrated and quantitative understanding of how fusion–fission dynamics control mitochondrial morphology has not yet been described. Here, we took advantage of modern visualisation techniques to provide a clear explanation of how fusion and fission correlate with mitochondrial length and motility in neurons. Our main findings demonstrate that: (1) the probability of a single mitochondrion splitting is determined by its length; (2) the probability of a single mitochondrion fusing is determined primarily by its motility; (3) the fusion and fission cycle is driven by changes in mitochondrial length and deviations from this cycle serves as a corrective mechanism to avoid extreme mitochondrial length; (4) impaired mitochondrial motility in neurons overexpressing 120Q Htt or Tau suppresses mitochondrial fusion and leads to mitochondrial shortening whereas stimulation of mitochondrial motility by overexpressing Miro-1 restores mitochondrial fusion rates and sizes. Taken together, our results provide a novel insight into the complex crosstalk between different processes involved in mitochondrial dynamics. This knowledge will increase understanding of the dynamic mitochondrial functions in cells and in particular, the pathogenesis of mitochondrial-related neurodegenerative diseases.

7 April 2006 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MGMithu Guha
Mithu Guha
SKSanjay Kumar
Sanjay Kumar
VCVinay Choubey
Vinay Choubey
PMPallab Maity
Pallab Maity
UBUday Bandyopadhyay
Uday Bandyopadhyay
Click on the article title to read more.

1 February 2007 in Life Sciences
Verified
Journal Article
Closed access
SKSanjay Kumar
Sanjay Kumar
MGMithu Guha
Mithu Guha
VCVinay Choubey
Vinay Choubey
PMPallab Maity
Pallab Maity
UBUday Bandyopadhyay
Uday Bandyopadhyay

19 July 2016 in PLOS Biology
Verified
Journal Article
Open access
PDF file
MCMichal Cagalinec
Michal Cagalinec
MLMailis Liiv
Mailis Liiv
ZHZuzana Hodurova
Zuzana Hodurova
Miriam A. HickeyMiriam A. Hickey
Miriam A. Hickey
AVAnnika Vaarmann
Annika Vaarmann
AKAllen Kaasik
Allen Kaasik
Deficiency of the protein Wolfram syndrome 1 (WFS1) is associated with multiple neurological and psychiatric abnormalities similar to those observed in pathologies showing alterations in mitochondrial dynamics. The aim of this study was to examine the hypothesis that WFS1 deficiency affects neuronal function via mitochondrial abnormalities. We show that down-regulation of WFS1 in neurons leads to dramatic changes in mitochondrial dynamics (inhibited mitochondrial fusion, altered mitochondrial trafficking, and augmented mitophagy), delaying neuronal development. WFS1 deficiency induces endoplasmic reticulum (ER) stress, leading to inositol 1,4,5-trisphosphate receptor (IP3R) dysfunction and disturbed cytosolic Ca2+ homeostasis, which, in turn, alters mitochondrial dynamics. Importantly, ER stress, impaired Ca2+ homeostasis, altered mitochondrial dynamics, and delayed neuronal development are causatively related events because interventions at all these levels improved the downstream processes. Our data shed light on the mechanisms of neuronal abnormalities in Wolfram syndrome and point out potential therapeutic targets. This work may have broader implications for understanding the role of mitochondrial dynamics in neuropsychiatric diseases. Wolfram syndrome (WS) is a genetic disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and brain atrophy. Brain abnormalities occur at the earliest stage of clinical symptoms, suggesting that Wolfram syndrome has a pronounced impact on early brain development. The majority of Wolfram syndrome cases are caused by mutations in the gene Wolfram syndrome 1 (WFS1), which encodes for a protein localized to the endoplasmic reticulum (ER) membrane. However, the clinical symptoms of WS resemble mitochondrial disease symptoms, suggesting strong mitochondrial involvement. In this manuscript, we demonstrate that deficiency of the gene WFS1 triggers an ER-stress cascade, which impairs the function of the IP3-receptor calcium channel, leading to altered calcium homeostasis. The latter leads to dysregulation of mitochondrial dynamics, as characterized by augmented mitophagy—a selective degradation of mitochondria—and inhibited mitochondrial trafficking and fusion, which results in lower levels of ATP and, thus, inhibits neuronal development. These results shed new light onto the mechanisms of neuronal abnormalities in Wolfram syndrome and point out potentially new therapeutic targets. Moreover, our results unravel two rather unexpected links that have an impact beyond the relatively rare Wolfram syndrome. First, relatively mild stress of the ER can seriously disturb mitochondrial dynamics, explaining why alterations at the level of the ER could lead to a mitochondrial phenotype. Second, increased levels of mitophagy, leading to excessive and unwanted mitochondrial clearance, are harmful for neurons. Furthermore, since alterations in the gene WFS1 take place in different neurologic and psychiatric disorders, our work may also have broad implications for understanding the role of mitochondrial dynamics in neuropsychiatric diseases.